MedPath

The incidence rate of Rifampin-resisitant Staphylococci after short term administration of rifaximin in cirrhotic patients

Not Applicable
Recruiting
Conditions
Codes for special purposes
Registration Number
KCT0001753
Lead Sponsor
Ewha Womans University Medical Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
180
Inclusion Criteria

Liver cirrhosis patient who taken rifaximin more than 7 days to prevent hepatic encephalopathy or to manage enterocolitis

Exclusion Criteria

1) who died or was follow up loss
2) who treated with rifampin
3) who administered rifaximin already
4) who judged that cannot be enrolled by researcher

Study & Design

Study Type
Observational Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Prevalence of rifampin resistant staphylococcus
Secondary Outcome Measures
NameTimeMethod
Rifampin-resistant Staphylococci carrier rate before administer rifaximin
© Copyright 2025. All Rights Reserved by MedPath